Related Experiment Videos
Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans
Letizia Mazzini1, Franca Fagioli, Riccardo Boccaletti
1Department of Neurology, University of Torino, Italy. mazzini.l@libero.it
Summary
This study shows that implanting autologous mesenchymal stem cells (MSCs) into the spinal cord is safe for amyotrophic lateral sclerosis (ALS) patients. The procedure was well-tolerated, with only minor, reversible side effects observed.
Area of Science:
- Neuroscience
- Regenerative Medicine
- Stem Cell Therapy
Background:
- Animal models of ALS show stem cells slow disease progression and prolong survival.
- Investigated the feasibility and safety of intraspinal cord implantation of autologous mesenchymal stem cells (MSCs) in ALS patients.
Purpose of the Study:
- To evaluate the safety and tolerability of autologous MSC transplantation into the spinal cord for ALS patients.
Main Methods:
- Autologous bone marrow-derived MSCs were expanded ex vivo.
- Cells were suspended in cerebrospinal fluid and transplanted via micrometric pump injector into the spinal cord.
Main Results:
- No major adverse events like respiratory failure or death occurred.
- Minor, reversible adverse events included intercostal pain and leg sensory dysesthesia.
- No abnormal cell proliferation or spinal cord volume changes were observed.
Conclusions:
- Ex vivo expansion and intraspinal transplantation of autologous MSCs are safe and well-tolerated in ALS patients.
- Supports the potential of stem cell therapy for ALS treatment.